|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DESCRIBEN EL TRATAMIENTO CON CORTICOIDES EN PACIENTES CON DISTROFIA MUSCULAR DE DUCHENNE (especial para SIIC © Derechos reservados) |
 |
Autor: David Feder Columnista Experto de SIIC Institución: Faculdade de Medicina do ABC Artículos publicados por David Feder |
|
Coautores Panosso Macedo Luiza* Schewed Razaboni Renata** Wohlers Sabo Helena** Perez Sacardo Karina** Aluna do 3º ano do curso de medicina, Faculdade de Medicina do ABC, São Paulo, Brasil* |
|
Recepción del artículo 14 de abril, 2009 |
Aprobación 27 de abril, 2009 |
|
Primera edición 19 de octubre, 2009 |
|
|
ResumoA distrofia muscular de Duchenne (DMD) é uma doença recessiva ligada ao cromossomo X (na região p21) que ocorre por uma mutação no gene responsável pela síntese da proteína distrofina que resulta em uma quantidade muito reduzida, nula ou em uma forma anormal dessa proteína. Até que a terapia molecular possa ser obtida somente os corticóides aumentaram temporariamente a função muscular. São utilizados os seguintes corticóides: prednisona e prednisolona (0.75 mg/kg) e deflazacort (0.9 mg/kg). Os corticóides aumentam massa muscular, retardam a velocidade de degeneração muscular, aumentam o tempo de deambulação e também a capacidade respiratória e cardíaca. No entanto, esteróides possuem diversos efeitos colaterais. O deflazacort causa menos efeitos colaterais, exceto a catarata. Os efeitos benéficos e colaterais dos corticóides precisam ser monitorizados de perto.
Palabras clavedistrofia muscular de Duchenne, cromossomo X, corticostróides, distrofia muscular de Duchenne, corticosteroides, prednisona, deflazacort Clasificación en siicsalud Artículos originales > Expertos de Iberoamérica > página www.siicsalud.com/des/expertocompleto.php/103722 Especialidades 
Principal: Neurología,
Pediatría
Relacionadas: Atención Primaria,
Farmacología,
Fisiatría,
Medicina Farmacéutica,
Medicina Familiar,
Medicina Interna
Enviar correspondencia a:David Feder, Faculdade de Medicina do ABC, São Paulo, Brasil, E-mail: david-feder@uol.com.br
Key wordsDuchenne muscular dystrophy, corticosteroids, prednisone, deflazacort
Bibliografía del artículo
1. Alman BA. Duchenne muscular dystrophy and steroids: pharmacologic treatment in the absence of effective gene therapy. Pediatr Orthop 25(4):554-6, 2005.2. Balaban B et al. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: Long-term effect. Am J Phys Med Rehabil 84:843-850, 2005. 3. Balagopal P et al. Oxandrolone enhances skeletal muscle and alters global gene expression profile in Duchenne muscular dystrophy. Am J Physiol Endocrinol Metab 209:530-539, 2005. 4. Beenakker EAC et al. Intermittent Prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 62:128-132, 2005. 5. Biggar WD et al. Deflazacort treatment of Duchenne muscular dystrophy. The J Pediatr 138(1):45-50, 2001. 6. Biggar WD et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16(4):249-55, 2006. 7. Bonifati DM et al. The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. J Neurol Neurosurg Psychiatry 77(10):1177-9, 2006. 8. Brunelli S et al. Nitric oxide release combined with nonsteroidal antiinflamatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. PNAS 104:264-269, 2007. 9. Bushby K, Griggs R. 145th ENMC International Workshop: Planning for a international trial of steroid dosage regimes in DMD (for DMD) Neuromuscul Disord 17:423-428, 2003. 10. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne muscular dystrophy: A systematic review. BMC Neurology 3:7, 2007. 11. Carter GT et al. Effect of voluntary wheel-running exercise on muscles of the mdx mouse. Neuromuscul Disord 5(4):323-32, 1995. 12. Chakkalakal JV et al. Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J 19(8):880-91, 2005. 13. Daftary AS et al. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 119:320-324, 2007. 14. Feder D. Langer AL. Uso dos corticóides no tratamento da Distrofia Muscular de Duchenne Jornal Brasileiro de Medicina 89(1):57-9, 2005. 15. Garrood P et al. Myoglobinuria in boys with Duchenne muscular dystrophy on corticosteroid therapy. Neuromuscul Disord 18:71-73, 2007. 16. Gati I et al. Effects of inhibitors of the arachidonic acid cascade on primary muscle culture from a Duchenne muscular dystrophy patient. Prostaglandins, Leukotrienes and Essential Falley Acids 77:217-223, 2007. 17. Hawker G et al. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchenne`s muscular dystrophy. Arch Phys Medicine and Rehabilitation 86(2):284-8, 2005. 18. Houde S et al. Deflazacort use in Duchenne muscular dystrophy: An 8-year follow-up. Pediatr Neurol 38:200-206, 2008. 19. Hussein MR et al. The effect of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. Int J Exp Pathol 87(6):451-61, 2006. 20. Kinali M et al. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. Eur J Paediatr Neurol 11:160-166, 2007. 21. King WM et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68(19):1607-13, 2007. 22. Kocabas S et al. Anesthesic management of a child with Duchenne muscular dystrophy undergoing correction of Fallot's Tetralogy. Pediatric Anesthesia 18:439-452, 2008. 23. Markham LW et al. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 26:768-771, 2005. 24. Markham LW et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 18:365-370, 2008. 25. Mavrogeni S et al. Effect og deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: A magnetic resonance imaging study. Eur J Paediat Neurol doi:10.1016/j.ejpn.2008.02.006, 2008. 26. Miura P et al. IRES-Mediated Translation of Utrophin a is enhance by glucocorticoid treatment in skeletal muscle cell. PLoS ONE 3(6)e2309. doi:10.1371/journal.pone0002309, 2008. 27. Moxley III RT ET al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standars Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64:13-20, 2005. 28. Muenster T et al. Reversal of rocuronium-induced neuromuscular blockade by pyridostigmine in patients with Duchenne muscular dystrophy. Pediat Anesthesia 18:251-25, 2008. 29. Parreira SLS et al. Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arq Neuropsiquiatria 65(2-A):254-250, 2007. 30. Pastoret C, Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurological Sciences 129:97-105, 1995. 31. Pradham S. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 253(10):1309-16, 2006. 32. Radley HG et al. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. IJBCB 39:469-477, 2007. 33. Söderpalm AC et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord 17:919-928, 2007 34. Stober JB. Therapeutics in Duchenne muscular dystrophy. NeuroRx 3(2):225-34, 2006. |
|
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
|
Acerca de SIIC Estructura de SIIC
|
 |
Sociedad Iberoamericana de Información Científica (SIIC) Av. Belgrano 430, (C1092AAR), Buenos Aires, Argentina Tel: +54 11 4342 4901; Fax: +54 11 4331 3305 Casilla de Correo 2568, (C1000WAZ) Correo Central, Buenos Aires Copyright siicsalud© 1997-2010, Sociedad Iberoamericana de Información Científica (SIIC) ISSN siicsalud: 1667-9008 ua062909 Mensajes a SIIC |
Artículos seleccionados para su compra
